Commissioner Dr. Martin Makary’s recent decision to tap outspoken FDA critic, Dr. Vinay Prasad, as head of the Center for Biologics Evaluation and Research has brought the agency’s future into sharper focus.
While Prasad’s views may not align with many of the FDA’s traditional policies, they do fit into a broader MAHA agenda of scrutinizing industry ties, questioning scientific norms and taking a more critical stance on vaccines.
Prasad’s appointment last week is the latest in a series of controversial FDA shakeups, including HHS Secretary Robert F. Kennedy Jr.’s move to slash thousands of FDA jobs, followed by new reports that some of those terminated workers will be rehired.
It’s also par for the course for the Trump administration, which has appointed a string of agency heads who are critical of, and even…